IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

PHASE3RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

April 24, 2026

Study Completion Date

October 24, 2029

Conditions
Chronic Myelomonocytic Leukemia
Interventions
DRUG

IMM01

IV infusion

DRUG

Azacitidine

subcutaneous injection

DRUG

Placebo

IV infusion

Trial Locations (43)

300020

RECRUITING

Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College;, Tianjin

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei

RECRUITING

China-Japan Friendship Hospita, Beijing

NOT_YET_RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

NOT_YET_RECRUITING

First Hospital of Lanzhou University, Lanzhou

RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

NOT_YET_RECRUITING

Shenzhen Second People's Hospital, Shenzhen

NOT_YET_RECRUITING

Zhujiang Hospital of Southern Medical University, Zhujiang

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

RECRUITING

Affiliated Hospital of Guizhou Medical University, Guiyang

NOT_YET_RECRUITING

Affiliated Hospital of Hebei University, Shijiazhuang

NOT_YET_RECRUITING

The Second Hospital of Hebei Medical University, Shijiazhuang

NOT_YET_RECRUITING

Harbin First Hospital, Harbin

RECRUITING

First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Henan Cancer Hospital, Zhengzhou

NOT_YET_RECRUITING

Henan Provincial People's Hospital, Zhengzhou

NOT_YET_RECRUITING

The First Affiliated Hospital of Henan University of Science and Technology, Zhengzhou

RECRUITING

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

NOT_YET_RECRUITING

Zhongnan Hospital Affiliated to Wuhan University, Wuhan

RECRUITING

Xiangyang Central Hospital, Xiangyang

NOT_YET_RECRUITING

Xiangya Hospital Central South University, Changsha

RECRUITING

Changzhou First People's Hospital, Changzhou

NOT_YET_RECRUITING

Jiangsu Province Hospital, Nanjing

RECRUITING

Zhongda Hospital affiliated to Southeast University, Nanjing

NOT_YET_RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

RECRUITING

Affiliated Hospital of Xuzhou Medical University, Xuzhou

RECRUITING

Jiangsu Subei People's Hospital, Yangzhou

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

The First Hospital of Jilin University, Changchun

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

NOT_YET_RECRUITING

The First Hospital of China Medical University, Shenyang

RECRUITING

Qilu Hospital of Shandong University, Jinan

RECRUITING

Shaanxi Provincial People's Hospital, Xi’an

NOT_YET_RECRUITING

Sichuan Provincial People's Hospital, Chengdu

RECRUITING

Yibin Second People's Hospital, Yibin

RECRUITING

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

NOT_YET_RECRUITING

The Second Affiliated Hospital of Kunming Medical University, Kunming

RECRUITING

Ningbo First Hospital, Ningbo

NOT_YET_RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

NOT_YET_RECRUITING

Peking University People's Hospital, Beijing

RECRUITING

Tianjin People's Hospital, Tianjin

All Listed Sponsors
lead

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

OTHER